Show simple item record

dc.contributor.authorMorton, A
dc.contributor.authorCantrill, J
dc.contributor.authorCraig, A
dc.contributor.authorHowell, Anthony
dc.contributor.authorDavies, M
dc.contributor.authorAnderson, D
dc.date.accessioned2010-11-22T15:24:45Z
dc.date.available2010-11-22T15:24:45Z
dc.date.issued1988-03-19
dc.identifier.citationSingle dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. 1988, 296 (6625):811-4 Br Med Jen
dc.identifier.issn0267-0623
dc.identifier.pmid3130925
dc.identifier.doi10.1136/bmj.296.6625.811
dc.identifier.urihttp://hdl.handle.net/10541/115975
dc.description.abstractThirty patients with hypercalcaemia and known malignant disease were randomly allocated to receive 60 mg 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) intravenously as a single dose or as consecutive daily doses of 30 mg (two days) or 15 mg (four days). The rate of infusion was the same for each regimen (7.5 mg/hour). Calcium concentrations fell in all patients and returned to normal in all but two. Relapse of hypercalcaemia occurred after a mean of 21 days in each group. Urinary calcium excretion fell in all groups and symptoms were greatly improved. After relapse patients were retreated with APD (30 mg as a single infusion) and normocalcaemia maintained by regular infusions at two to three week intervals. APD given as a single 60 mg infusion over eight hours together with rehydration is recommended as the initial management of the hypercalcaemia of malignancy, followed by 30 mg APD roughly every two to three weeks to maintain normal or near normal serum calcium concentrations.
dc.language.isoenen
dc.subject.meshCalcium
dc.subject.meshDiphosphonates
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypercalcemia
dc.subject.meshInfusions, Intravenous
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshRandom Allocation
dc.subject.meshTime Factors
dc.titleSingle dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.en
dc.typeArticleen
dc.contributor.departmentHope Hospital, Salford.en
dc.identifier.journalBritish Medical Journalen
html.description.abstractThirty patients with hypercalcaemia and known malignant disease were randomly allocated to receive 60 mg 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) intravenously as a single dose or as consecutive daily doses of 30 mg (two days) or 15 mg (four days). The rate of infusion was the same for each regimen (7.5 mg/hour). Calcium concentrations fell in all patients and returned to normal in all but two. Relapse of hypercalcaemia occurred after a mean of 21 days in each group. Urinary calcium excretion fell in all groups and symptoms were greatly improved. After relapse patients were retreated with APD (30 mg as a single infusion) and normocalcaemia maintained by regular infusions at two to three week intervals. APD given as a single 60 mg infusion over eight hours together with rehydration is recommended as the initial management of the hypercalcaemia of malignancy, followed by 30 mg APD roughly every two to three weeks to maintain normal or near normal serum calcium concentrations.


This item appears in the following Collection(s)

Show simple item record